IL‐2 is the first immunotherapy to receive approval for cancer treatment, and a total of 36 IL‐2‐based compounds have entered clinical trials for oncology, with most of these agents still in the early stages of evaluation [362]. The gene discussed is IL2; the disease is cancer.